

Institutional Biosafety Committee (IBC) Meeting Minutes

DATE:	December 1, 2025
TIME:	3:05 PM – 3:39 PM
LOCATION:	Allen Institute - Virtual (Teams)
SUBJECT:	IBC Meeting Minutes (NIH)
COMMITTEE MEMBERS PRESENT: (9 VOTING)	Irina Mueller (IBC Chair); Jennifer Allen (EHS); Molly Gasperini (Scientist); Meagan Quinlan (Scientist); Julian Reading (Scientist); Julie Nyhus (Scientist); Tim Dawe (Animal Containment Expert); Yoh Isogai (Scientist); Sierra Hansen (non-affiliated) <i>The IBC has 10 voting members with 1 alternate member (EHS), and 6 members are required to conduct business.</i>
MEMBERS ABSENT:	Susan Bell (non-affiliated); Grant Lee (EHS, alternate)
OTHER ATTENDEES:	Shannon Ramsey (Research Compliance); Bernie Frankel (Research Compliance)

Call to Order	The IBC Chair called the meeting to order at 3:05 PM.
Conflict of Interest	Standard meeting reminders about preparation, confidentiality, and recusals. The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.
Review and approval of previous meeting minutes	09/29/25 NIH meeting minutes to be approved <ul style="list-style-type: none"> • Motion: Approve the minutes as written • Votes: 7 For / 0 Against / 2 Abstain [YI, SH]
Review of Current and Prior Business	Due to the transparency initiatives requiring public posting of IBC meeting minutes, we will separate NIH regulated and non-NIH regulated business matters into two separate meetings and meeting minutes going forward.

1. IBC Review	
PI Name(s)	Ed Lein
Registration Number/Title	005-2025 Human Cell Types (HCT)
Protocol Overview	<p>Summary: 3-year renewal for 005-2022 Registration</p> <p>Risk Group 2 Materials [No change]: Recombinant Herpes Simplex Virus, Adenovirus Type 5, Tetradotoxin, Sindbis Virus, and Tetanus Toxin Light Chain, and wild-type postmortem nonhuman primate, armadillo, other Risk Group 2 mammals, and harbor porpoise tissues.</p> <p>Risk Group 1 Materials [No change]: Recombinant AAV and plasmid DNA</p> <p>Training Verification: N/A</p> <p>Applicable section(s) of NIH Guidelines: III-D, III-E [No change]</p> <p>COI / Recused: Julie Nyhus, Meagan Quinlan</p> <p>There were no significant changes to the renewal. Minor changes included updates to Attachment A Personnel form and administrative updates to correct outdated links and safety instructions in the Biohazard Profile and Procedure forms. Pre-review was performed by a Scientist and the EHS Director.</p> <p>During the review, the following administrative updates were requested:</p> <ol style="list-style-type: none"> 1. Confirm that all hyperlinks in IBC Registration and Biohazard forms are live and update as needed. 2. Update template language in Biohazard forms with the current EHS recommendations, specifically in the PPE section.

Institutional Biosafety Committee (IBC) Meeting Minutes

	<p>3. Biohazard Profile forms (for agents that will be cell sorted); Section 5: Include “Additional Information” that cell sorting this Risk Group 2 material requires secondary containment. Only Risk Group 1 materials may be used in uncontained equipment.</p> <ul style="list-style-type: none"> • Motion: Approve 005-2025 IBC Registration Renewal with administrative updates. • Votes: 7 For / 0 Against / 2 Recused [JN, MQ]
--	---

2. IBC Pre-Approval Confirmation	
PI Name(s)	Maximilian Heeg
Registration Number/Title	013-2024 Immunology (Animal) IBC Registration - Amendment #6
Overview	<p>Summary: Add Vero CCL-81 cells to use for plaque assay Risk Group 2 Materials: No change New Risk Group 1 Materials: Vero CCL-81 cells Training Verification: N/A Applicable section(s) of NIH Guidelines: III-D, III-E [No change] COI / Recused: None</p> <p>No significant changes were required for this amendment. Pre-approval review was performed by the IBC Chair and EHS Director. Pre-approval was provided by IBC Chair.</p> <p>During the review, no additional questions or updates were requested.</p> <ul style="list-style-type: none"> • Motion: Approve 013-2024 Amendment #6 • Votes: 9 For / 0 Against / 0 Abstain

3. IBC Pre-Approval Confirmation	
PI Name(s)	Jesse Gray
Registration Number/Title	012-2023 SeaHub IBC Registration - Amendment #5
Overview	<p>Summary: Updated Proaerolysin Biohazard form to remove conflicting information regarding animal use. Proaerolysin is used for cell culture only. Risk Group 2 Materials: No change New Risk Group 1 Materials: None; Clarification in Proaerolysin form only Training Verification: BSL2+ Training is required to use this material in bulk/powdered form. Applicable section(s) of NIH Guidelines: III-D, III-E, III-F COI / Recused: Molly Gasperini</p> <p>No significant changes were required for this amendment. Pre-review was performed by the IBC Chair and EHS Director. Pre-approval was provided by IBC Chair.</p> <p>During the review, no additional questions or updates were requested.</p> <ul style="list-style-type: none"> • Motion: Approve 012-2023 Amendment #5 • Votes: 8 For / 0 Against / 1 Recused [MG]

Other Business	
	None

Adjourn	The IBC Chair adjourned the meeting at 3:39 PM.
----------------	---